ERBB2 and pancreatic neoplasm: Recently, improved understanding of the molecular mechanisms responsible for the acquired or inherent resistance of pancreatic cancer cells towards EGFR- or HER-2 targeted therapy suggested that combination therapy based on agents targeting both receptors and/or multiple pathways supporting proliferation of cancer cells might represent a more efficacious treatment approach towards this disease.